Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors during the central nervous technique, conolidine modulates alternate molecular targets. A Science Advances review uncovered that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR